In the context of GPER, AbTAC and LYTAC strategies offer a promising avenue for overcoming the limitations of traditional degraders and hold significant clinical potential for ER+/GPER+ breast cancer (390, 413). This evidence concerns the gene GPER1 and breast cancer.